Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 241

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1A
Chunk 241
---
holders includes any beneficial owners of
common shares held in street name.

Dividend Policy

We have not paid any dividends
on our common stock to date and do not anticipate that we will pay dividends in the foreseeable future. Any payment of cash dividends
on our common stock in the future will be dependent upon the amount of funds legally available, our earnings, if any, our financial condition,
our anticipated capital requirements and other factors that the Board of Directors may think are relevant. However, we currently intend
for the foreseeable future to follow a policy of retaining all of our earnings, if any, to finance the development and expansion of our
business and, therefore, do not expect to pay any dividends on our common stock in the foreseeable future.

Recent Sales of Unregistered Securities

The Company did not have any
sales of unregistered securities during the period covered by this Annual Report, other than those disclosed in our Form 8-K filed on
March 17, 2025, which were exempt from registration under Section 4(a)(2) of the Securities Act.

Securities Authorized for Issuance Under Equity
Compensation Plans

Information about our equity
compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

The following discussion and
analysis should be read in conjunction with the consolidated Financial Statements and Notes thereto appearing elsewhere in this Annual
Report.

We are a medical therapeutic
company focused on developing the Hemopurifier® (HP), a clinical-stage immunotherapeutic device intended for applications in cancer,
life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In human studies (164 sessions
with 38 patients), the Hemopurifier was used safely and demonstrated the potential to remove enveloped viruses. In pre-clinical studies,
the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids,
utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune
suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The U.S. Food and Drug
Administration (“FDA”) has designated the Hemopurifier as a “Breakthrough Device” for two independent indications:

    ·
    the